POST Online Media Lite Edition


Champions Oncology appoints Philip Breitfeld to board

Staff writer |
Hackensack, N.J., USA - April 14, 2016, Hackensack, N.J., USA - Champions Oncology announced the appointment of Philip Breitfeld to its board of directors.

Article continues below

Dr. Breitfeld has more than 30 years of experience in oncology. He was most recently Global Vice President at Quintiles, responsible for the Therapeutic Centers of Excellence. Prior to that, he led the Oncology Center of Excellence at Quintiles.

Dr. Breitfeld held senior clinical development positions at Merck KGaA (EMD Serono in the U.S.), where he led oncology development in the US, and at BioCryst, where he led oncology development and was Associate Chief Medical Officer.

Prior to his career in industry, Dr. Breitfeld held academic positions at Harvard, University of Massachusetts, Indiana University, and Duke. He has approximately 50 publications in the literature.


What to read next

Helsinn Therapeutics (U.S.), Inc. strengthens its board of directors
US Oncology: R. Dale Ross to retire, Bruce Broussard chairman of the board
United Continental Holdings names Edward Philip to board